CaseVu
Precipio Announces Year end 2023 Shareholder Update Call
Conference Call to be held on April 1st, 2024 at 5:00 PM EST NEW HAVEN, [...]
Mar
Precipio to Report $15.2M for FY-2023 (unaudited) Revenues, an increase of 60% YoY
Company continues to make strides towards breakeven NEW HAVEN, CT, Globenewswire – (February 13, 2024) – [...]
Feb
Precipio and Cardinal Health Sign Distribution Agreement for its HemeScreen® Portfolio of Molecular assays for Cancer
NEW HAVEN, CT, Globenewswire – (February 6, 2024) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: [...]
Feb
Precipio’s Q4-2023 Cash Burn From Operations (unaudited) drops below $100K for the full quarter
Results clearly demonstrate the business’s ability to reach breakeven in the near future NEW HAVEN, [...]
Jan
Precipio Signs Distribution Agreement For IV-Cell® and HemeScreen® in Japan
First order for IV-Cell placed by Major Japanese Laboratory NEW HAVEN, CT, Globenewswire – (January [...]
Jan
Precipio Announces Christina Valauri joins the Board of Directors
Douglas Fisher, MD will step down as Director, and remain as a board observer NEW [...]
Jan
Precipio Management Shares Thoughts on 2023, and Looks Ahead To 2024
NEW HAVEN, CT, Globenewswire – (December 14, 2023) – Management of specialty cancer diagnostics company Precipio, [...]
Dec
Precipio Announces Q3-2023 Shareholder Update Call
Conference Call to be held on November 20th, 2023 at 5:00 PM EST NEW HAVEN, [...]
Nov
Precipio to Report $4.5M Q3-2023 Revenues, Double From Q3-2022
28% Revenue Increase is Major Step toward Company Breakeven NEW HAVEN, CT, Globenewswire – (October [...]
Oct
Precipio’s Q3 Cash Burn From Operations (unaudited) Declines 59% YoY, from $2.5M in Q3-2022 to approximately $1M in Q3-2023
Company anticipates current cash levels sufficient to reach breakeven NEW HAVEN, CT, Globenewswire – (October [...]
Oct